Clinical Trial Update: A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT [Phase 4]

View source ↗

Summary

A Phase 4 trial suggests that reducing the dose of anti-thymoglobulin (ATG) lowers chronic graft-versus-host disease without raising leukemia relapse in patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia Relapse

Drugs mentioned

• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Zhujiang Hospital | Conditions: Chronic Graft-versus-host-disease, Leukemia Relapse | Phase 4 | Status: UNKNOWN